Scientists Debate Safety and Ethics of Embryo Genome Editing to Prevent Disease

New research suggests genome editing could reduce disease risks, but experts warn of significant technical, ethical, and societal challenges.

A new study explores the potential of polygenic genome editing to lower risks for diseases like Alzheimer's, heart disease, and diabetes by modifying multiple DNA variants in human embryos.
Researchers highlight that current gene-editing technologies, including CRISPR, are not yet safe or precise enough for widespread use in embryos.
Critics warn of unpredictable risks, including unintended genetic effects, pleiotropic consequences, and ethical concerns such as the potential for eugenics and inequitable access.
The study emphasizes that many diseases have non-genetic causes, limiting the effectiveness of genome editing as a universal solution.
Experts call for extensive societal discussions and regulatory frameworks to address the ethical and social implications before the technology becomes viable in future decades.